HONG KONG – GNT Pharma Co. Ltd., of Yongin City, South Korea, has finished the patient enrollment for a phase II trial of its multitarget neuroprotection candidate, Neu-2000, in China, with top-line results from the trial, known as ENIS, expected in the first half of this year.
HONG KONG – GNT Pharma Co. Ltd., of Yongin City, South Korea, has finished the patient enrollment for a phase II trial of its multitarget neuroprotection candidate, Neu-2000, in China, with top-line results from the trial, known as ENIS, expected in the first half of this year.
HONG KONG – South Korean biotech company Samsung Bioepis Co. Ltd. has entered a licensing agreement with China's 3Sbio Inc. to expand its biosimilars business to mainland China. The agreement covers multiple biosimilar candidates from the Incheon-based Samsung Bioepis, including SB-8, a biosimilar to blockbuster anti-VEGF antibody Avastin (bevacizumab, Genentech Inc./Roche Holding AG) that is undergoing phase III trials.
HONG KONG – Chugai Pharmaceutical Co. Ltd. is ending the year on a winning streak. The Japanese pharmaceutical company recently reported that its satralizumab had achieved the primary endpoint in a phase III monotherapy study in neuromyelitis optica spectrum disorder (NMOSD), which currently has no approved treatments.
HONG KONG – Astellas Pharma Inc. proceeded with an exclusive option to acquire Potenza Therapeutics Inc. under a warrant purchase agreement. Tokyo-based Astellas paid Potenza an up-front fee of $164.6 million to acquire the Cambridge, Mass.-based biopharma. Upon closing, Potenza will be a wholly owned subsidiary. Shareholders of Potenza will be in for a windfall, as they are eligible for additional payments that total up to $240.1 million, depending on the progress of the various programs in clinical development.
HONG KONG – Astellas Pharma Inc. proceeded with an exclusive option to acquire Potenza Therapeutics Inc. under a warrant purchase agreement. Tokyo-based Astellas paid Potenza an upfront fee of $164.6 million to acquire the Cambridge, Mass.-based biopharma.
HONG KONG – Olympus Medical Systems Corp. has been fined $85 million by the U.S. Department of Justice (DOJ) after it failed to report details of three outbreaks related to its endoscope technology. The Tokyo-based company failed to file two required supplemental Medical Device Reports (MDRs) and one initial MDR to the U.S. FDA for events in Europe in connection with its 'TJF-Q180V' duodenoscopes.
